These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2656617)

  • 1. L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals.
    Gilfillan EC; Pelak BA; Weissberger BA; Abruzzo GK; Fromtling RA; Bland JA; Hadley SK; Gadebusch HH
    J Antibiot (Tokyo); 1989 May; 42(5):815-22. PubMed ID: 2656617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy.
    Gilfillan EC; Pelak BA; Fromtling RA; Bland J; Hadley S; Gadebusch HH
    J Antibiot (Tokyo); 1988 Aug; 41(8):1137-41. PubMed ID: 3049491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.
    Fantin B; Farinotti R; Thabaut A; Carbon C
    J Antimicrob Chemother; 1994 Mar; 33(3):563-9. PubMed ID: 8040120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.
    Pechère JC; Vladoianu IR
    J Antimicrob Chemother; 1992 May; 29(5):563-73. PubMed ID: 1624394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals.
    Klesel N; Limbert M; Schrinner E; Seeger K; Seibert G; Winkler I
    Infection; 1984; 12(4):286-92. PubMed ID: 6092278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.
    Clumeck N; Van Laethem Y; Gordts B; Jaspar N; Butzler JP
    Antimicrob Agents Chemother; 1983 Aug; 24(2):176-80. PubMed ID: 6357068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice.
    Fu KP; Hetzel N; Hung PP; Gregory FJ
    Chemotherapy; 1986; 32(2):166-72. PubMed ID: 3698725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2004 Jun; 53(6):1098-100. PubMed ID: 15128727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
    Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
    Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime therapy of serious bacterial infections.
    Eron LJ; Goldenberg RI; Park CH; Poretz DM
    Antimicrob Agents Chemother; 1983 Feb; 23(2):236-41. PubMed ID: 6340601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR
    Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime--a new extended-spectrum cephalosporin.
    Gozzard DI; Geddes AM; Farrell ID; Eykyn SJ; Phillips I; Wise R; Brown RM
    Lancet; 1982 May; 1(8282):1152-6. PubMed ID: 6122940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.
    Maslow MJ; Rosenberg A; Pollock AA; Press RA; Silverman D; El-Sadr W; Richmond AS; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():213-7. PubMed ID: 6413486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enterobacter cloacae related meningitis].
    Roca B; Peris ML; Chumillas C; González-Darder JM
    Rev Neurol; 1999 Nov 16-30; 29(10):992. PubMed ID: 10637854
    [No Abstract]   [Full Text] [Related]  

  • 15. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P; Ryan DM; Sowa MA; Watts CM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. German Multicentre Study Group.
    Höffken G; Pasold R; Pflüger KH; Finke J; Fauser AA; Szelenyi H; Wagner J
    J Antimicrob Chemother; 1999 Sep; 44(3):367-76. PubMed ID: 10511404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic and kinetic properties of ceftazidime in animals.
    Acred P
    Infection; 1983; 11 Suppl 1():S44-8. PubMed ID: 6339418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.
    Tomatsu K; Ando S; Masuyoshi S; Hirano M; Miyaki T; Kawaguchi H
    J Antibiot (Tokyo); 1986 Nov; 39(11):1584-91. PubMed ID: 3539901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG; Bradford PA; Yates K; Newell P
    J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.